There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opthea Limited Sponsored ADR (OPT – Research Report) and Humacyte (HUMA – Research Report) with bullish sentiments.
Opthea Limited Sponsored ADR (OPT)
In a report released today, Sean Kim PhD from JonesTrading initiated coverage with a Buy rating on Opthea Limited Sponsored ADR and a price target of $15.00. The company’s shares closed last Thursday at $3.96, close to its 52-week low of $3.25.
According to TipRanks.com, PhD is a 5-star analyst with an average return of
Currently, the analyst consensus on Opthea Limited Sponsored ADR is a Strong Buy with an average price target of $19.00.
See today’s best-performing stocks on TipRanks >>
Humacyte (HUMA)
In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Humacyte, with a price target of $8.00. The company’s shares closed last Thursday at $3.23.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of
Humacyte has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OPT:
